Bibliographic Details
| Title: |
The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective. |
| Authors: |
Perry WL 3rd; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. bperry@lilly.com, Weitzman A |
| Source: |
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2005 Mar; Vol. 3 (3), pp. 199-202, 237-8. |
| Publication Type: |
Journal Article; Review |
| Journal Info: |
Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN: 1543-0790 (Print) Linking ISSN: 15430790 NLM ISO Abbreviation: Clin Adv Hematol Oncol Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
